M. A. Plaizier

Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line

A. Geldof, M. A. Plaizier, I. Duivenvoorden, 2003, Journal of Cancer Research and Clinical Oncology.

Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.

M. A. Plaizier, P. Kenemans, R. Verheijen, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies

R. DeJager, M. A. Plaizier, G. Teule, 1994, European Journal of Nuclear Medicine.

Feasibility of a randomized trial on adjuvant radio‐iodine therapy in differentiated thyroid cancer

J. Coebergh, P. Lips, D. Kuik, 2003, Clinical endocrinology.

Absorbed dose distribution of the auger emitters 67GA and 125I and the beta-emitters 67CU, 90Y, 131I, and 186RE as a function of tumor size, uptake, and intracellular distribution.

G. Barendsen, M. A. Plaizier, G. Teule, 1996, International journal of radiation oncology, biology, physics.

Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients.

R. DeJager, M. A. Plaizier, H. Haisma, 1991, Journal of the National Cancer Institute.

Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.

G. Snow, G. V. van Dongen, R. de Bree, 1997, British Journal of Cancer.

Calculation of the radiation dose at a bone-to-marrow interface.

M. A. Plaizier, G. Teule, A. van Lingen, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a feasibility study.

M. A. Plaizier, G. Teule, P. Huijgens, 1995, British Journal of Cancer.